UroGen Pharma Ltd. (URGN) Earnings History
Annual and quarterly earnings data from 2013 to 2025
Loading earnings history...
URGN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
URGN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 88.7% | -113.7% | -139.8% |
| 2024 | 90.2% | -107.1% | -140.4% |
| 2023 | 88.7% | -79.2% | -123.6% |
| 2022 | 88.1% | -122.8% | -170.6% |
| 2021 | 89.3% | -192.1% | -230.7% |
Download Data
Export URGN earnings history in CSV or JSON format
Free sign-in required to download data
UroGen Pharma Ltd. (URGN) Earnings Overview
As of May 8, 2026, UroGen Pharma Ltd. (URGN) reported trailing twelve-month net income of -$133M, reflecting -7.8% year-over-year growth. The company earned $-2.65 per diluted share over the past four quarters, with a net profit margin of -139.8%.
Looking at the long-term picture, URGN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2016.
UroGen Pharma Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PCVX (-$947M net income), SUPN (-$29M net income, -5.4% margin), PRGO (-$1.82B net income, -33.5% margin), URGN has comparable earnings metrics. Compare URGN vs PCVX →
URGN Earnings vs Peers
Earnings metrics vs comparable public companies
URGN Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$153M | -21.0% | -$125M | $-3.19 | -139.8% | -113.7% |
| 2024 | -$127M | -24.1% | -$97M | $-2.96 | -140.4% | -107.1% |
| 2023 | -$102M | +6.9% | -$66M | $-3.55 | -123.6% | -79.2% |
| 2022 | -$110M | +0.9% | -$79M | $-4.79 | -170.6% | -122.8% |
| 2021 | -$111M | +13.7% | -$92M | $-4.96 | -230.7% | -192.1% |
| 2020 | -$128M | -22.2% | -$127M | $-5.90 | -1088.9% | -1074.2% |
| 2019 | -$105M | -39.0% | -$109M | $-4.90 | -584144.4% | -608211.1% |
| 2018 | -$76M | -278.3% | -$77M | $-4.80 | -6707.2% | -6842.2% |
| 2017 | -$20M | -930.4% | -$20M | $-2.06 | -245.2% | -244.5% |
| 2016 | -$2M | +84.7% | $798,000 | $-0.16 | -11.1% | 4.6% |
See URGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs URGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare URGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonURGN — Frequently Asked Questions
Quick answers to the most common questions about buying URGN stock.
Is URGN growing earnings?
URGN EPS fell to $-2.65, with earnings declining -7.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-133M.
What are URGN's profit margins?
UroGen Pharma Ltd. net margin is -139.8%, with operating margin at -113.7%. Below-average margins reflect competitive or cost pressures.
How consistent are URGN's earnings?
URGN earnings data spans 2013-2025. The declining earnings trend is -7.8% YoY. Historical data enables comparison across business cycles.